Swiss drugmaker Novartis said it has applied to start selling its experimental drug to treat smoker's cough -- which afflicts 80 million people worldwide -- after tests showed that it helped patients breathe more easily.
Analysts say Novartis could earn billions of dollars if its treatments for chronic obstructive pulmonary disease (COPD), commonly known as smoker's cough, win regulatory approval. NVA237 alone could potentially add $500 million in annual sales.
Novartis seeks approval for new smoker's cough drug - Yahoo! News
thats billions with a B. of course we know that smokers cough can be fixed by switching to e-cigs but big pharma wouldn't get their fat stacks of cash. they just keep on dancin' around the cure. they've got a gum for this, a pill for that, an inhaler for the other thing. all the while people keep dying. plenty of treatments but they fight tooth&nail to keep the cure out of peoples hands.
Analysts say Novartis could earn billions of dollars if its treatments for chronic obstructive pulmonary disease (COPD), commonly known as smoker's cough, win regulatory approval. NVA237 alone could potentially add $500 million in annual sales.
Novartis seeks approval for new smoker's cough drug - Yahoo! News
thats billions with a B. of course we know that smokers cough can be fixed by switching to e-cigs but big pharma wouldn't get their fat stacks of cash. they just keep on dancin' around the cure. they've got a gum for this, a pill for that, an inhaler for the other thing. all the while people keep dying. plenty of treatments but they fight tooth&nail to keep the cure out of peoples hands.